SANDRIL Drug Patent Profile
✉ Email this page to a colleague
When do Sandril patents expire, and what generic alternatives are available?
Sandril is a drug marketed by Lilly and is included in two NDAs.
The generic ingredient in SANDRIL is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SANDRIL?
- What are the global sales for SANDRIL?
- What is Average Wholesale Price for SANDRIL?
Summary for SANDRIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Patent Applications: | 1,258 |
| DailyMed Link: | SANDRIL at DailyMed |
US Patents and Regulatory Information for SANDRIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | SANDRIL | reserpine | INJECTABLE;INJECTION | 010012-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | SANDRIL | reserpine | TABLET;ORAL | 009376-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | SANDRIL | reserpine | TABLET;ORAL | 009376-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
